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Mutation of the Mitochondrial Tyrosyl-tRNA
Synthetase Gene, YARS2, Causes Myopathy, Lactic
Acidosis, and Sideroblastic Anemia—MLASA Syndrome
Lisa G. Riley,1 Sandra Cooper,2,3 Peter Hickey,4 Joe¨lle Rudinger-Thirion,5 Matthew McKenzie,6
Alison Compton,7 Sze Chern Lim,7,8 David Thorburn,7,8 Michael T. Ryan,6 Richard Giege´,5
Melanie Bahlo,4 and John Christodoulou1,3,9,*
Mitochondrial respiratory chain disorders are a heterogeneous group of disorders in which the underlying genetic defect is often
unknown. We have identiﬁed a pathogenic mutation (c.156C>G [p.F52L]) in YARS2, located at chromosome 12p11.21, by using
genome-wide SNP-based homozygosity analysis of a family with affected members displaying myopathy, lactic acidosis, and sideroblas-
tic anemia (MLASA). We subsequently identiﬁed the same mutation in another unrelated MLASA patient. The YARS2 gene product,
mitochondrial tyrosyl-tRNA synthetase (YARS2), was present at lower levels in skeletal muscle whereas ﬁbroblasts were relatively normal.
Complex I, III, and IV were dysfunctional as indicated by enzyme analysis, immunoblotting, and immunohistochemistry. A mitochon-
drial protein-synthesis assay showed reduced levels of respiratory chain subunits in myotubes generated from patient cell lines. A tRNA
aminoacylation assay revealed that mutant YARS2 was still active; however, enzyme kinetics were abnormal compared to the wild-type
protein. We propose that the reduced aminoacylation activity of mutant YARS2 enzyme leads to decreased mitochondrial protein
synthesis, resulting inmitochondrial respiratory chain dysfunction. MLASA has previously been associated with PUS1mutations; hence,
the YARS2 mutation reported here is an alternative cause of MLASA.Introduction
Mitochondrial respiratory chain (RC) disorders are among
themostcommoninbornerrorsofmetabolism,withan inci-
dence of at least 1 in 8000 births, and are one of the most
challenging to diagnose, treat, or prevent.1 Diagnosis of RC
disorders is usually dependent on demonstration of altered
activities of one or more of the RC enzyme complexes. In
up to 50% of cases, RC enzyme deﬁciencies can only be
detected in muscle or liver biopsy samples and do not
manifest in ﬁbroblasts, making diagnosis more complex.2
For the ﬁve RC enzyme complexes to be functional, 13
mitochondrially encoded subunits and more than 75
nuclear-encoded subunits must be expressed in a coordi-
natedmanner.3 In addition, there are a number of essential
nuclear-encoded proteins that are involved in regulation of
mitochondrialDNA (mtDNA) transcription and translation
and RC subunit assembly and stability. Mutations in any of
these genes may result in a mitochondrial RC disorder.
Myopathy, lactic acidosis, and sideroblastic anemia
(MLASA [MIM 600462]) is a mitochondrial RC disorder
characterized by progressive exercise intolerance and side-
roblastic anemia. Severity of symptoms varies between and
within affected families and sometimes includes mental
retardation.4,5 MLASA is associated with a mutation in
pseudouridylate synthase 1 (PUS1 [MIM 610957]), result-
ing in decreased pseudouridylation of some cytoplasmic1Genetic Metabolic Disorders Research Unit, Children’s Hospital at Westmead
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In the present study, we performed genome-wide SNP
analyses of a consanguineous family with two children
affected by MLASA. We identiﬁed a c.156C>G (p.F52L)
mutation at chromosome 12p11.21 in YARS2 (MIM
610957) in the affected children and another MLASA
patient. This tyrosyl-tRNA synthetase catalyzes covalent
binding of tyrosine to its cognate tRNA. Functional studies
of recombinant p.F52L YARS2 protein showed that the
mutant protein had reduced catalytic efﬁciency.
Material and Methods
Clinical Information
The Ethics Committee of the Children’s Hospital at Westmead
approved this research, and, as required by that approval, written
consent was obtained from adult family members.
Family 1
The proband (II:2; Figure 1), the second child of ﬁrst-cousin
parents of Lebanese background, was born at term after an uncom-
plicated pregnancy and delivery. At around 10 weeks of age, pallor
and lethargy became apparent, and he was found to have sidero-
blastic anemia. He became transfusion dependent, initially
requiring packed cell transfusions every 2–3 months and in later
years every 3–4 weeks.
He was further investigated at 3 months of age because of failure
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Human 32 HSGAQGLLAAQKARGLFKDFFPETGTKIELPELFDRGT-ASFPQTIYCGFDPTADSLHVGHLLALLGLFHLQRA
Bovine 32 HSAAQGLLAVQKARGLFKEFFPEKGTKTELPELFDRGTGGKFPQTIYCGFDPTADSLHVGHLLALLGLFHFQRA
Rat 26 RPGARGMLVAPRARGLFKEFFPESGTKTELPELFDRRRAGS-PQTVYCGFDPTGDSLHVGHLLTLLGLFHFQRA
Mouse 26 RPGARGMLVAPRARGLFKEFFPESGTKTELPELFDRRRAGSSPQTVYCGFDPTGDSLHVGHLLTLLGLFHFQRA
Puffer fish 38 STLLNGLLFSLYKRGVLKESFPESAAQDQLPQLLQAGS-----QTVYCGFDPTADSLHVGNLLALIALLHFRNA
Fruit fly 21 RQMSQKNLLELTDRGFFHGIFPDTAAP-RMKQLFTRGQ-----QSIYAGFDPTADSLHVGNLLVIMGLIHCQRA
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Figure 1. Identification of a Mutation in YARS2 Associated with MLASA
(A) Pedigree of the family used for homozygosity mapping.
(B) DNA sequence identifying the c.156C>G (p.F52L) YARS2 mutation.
(C) Schematic diagram of YARS2 domains showing location of the variant F52 residue and its conservation among species. The following
abbreviations are used: MTS, mitochondrial targeting sequence; catalytic, catalytic domain; ACB, anticodon binding domain; and
S4-like, S4 ribosomal protein-like domain.(ranging over the years from 3 to 13.7 mmol/l; normal range
0.7–2.0 mmol/l) and hypertrophic cardiomyopathy, the latter of
which subsequently resolved without speciﬁc therapy. Pyridoxal
phosphate and thiamine appeared to have no impact on the
anemia. He was commenced on iron chelators—to prevent iron
overload in infancy—which were initially delivered subcutane-
ously and, in later years, orally.
Early gross and ﬁne motor development was normal, and
cognition was normal, with above-average school performance.
However, he suffered from chronic lethargy and progressive exer-
cise intolerance. By the age of 7 years he could no longer walk long
distances or climb stairs. Hearing and vision remained normal. At
17 years of age, cardiomyopathy was again noted, and by this time
he was essentially restricted to a wheelchair, although he was able
to walk short distances on a level surface. He had also developed
dysphagia, with intermittent choking with meals.
At 17 years 10 months he developed acute respiratory difﬁcul-
ties not preceded by eating or drinking nor associated with an
intercurrent illness, and he suffered an acute respiratory arrest,
requiring ventilatory support. At that time his weight was
40.4 kg (<3rd percentile) and height was 160.4 cm (<3rd percen-Thtile). Further investigations found no evidence of an acute cardiac
ischemic event, myocarditis, or pulmonary embolus. Over the
next 3 months there were a number of attempts to wean him
from mechanical ventilation, which were not successful. There
was no deterioration in cognitive abilities throughout this time.
He developed permanent vocal cord paresis and required enteral
nutritional support. After extensive discussion with the patient
and his parents, he elected to have heroic therapeutic measures
withdrawn, and he succumbed shortly thereafter.
A muscle biopsy at 2 years of age showed many regions of
subsarcolemmal mitochondrial aggregates and some incipient
‘‘ragged red’’ ﬁbers on histology, clearly decreased cytochrome
oxidase staining intensity, but a more subtle reduction in the
amount of NADH-tetrazolium reductase and succinate dehydroge-
nase staining. Lipid and glycogen staining was normal. Muscle
mitochondrial RC enzymology showed low activities of
complexes I and IV (Table 1). Fibroblast RC activities were normal.
Molecular testing for some of the common mtDNA mutations
(m.3243A>G, m.8344A>G, m.8993T>G, and m.8993T>C) and
for mtDNA deletions was normal. In addition, sequencing of the
PUS1 gene was normal (kindly performed by N. Fischel-Ghodsian,e American Journal of Human Genetics 87, 52–59, July 9, 2010 53
Table 1. RC Enzyme Activity in Skeletal Muscle of Individuals with the YARS2 Mutation
Enzyme Activity (% of Control Mean Relative to Citrate Synthase)
Enzyme Family 1, Patient 1 (II:2) Family 2, Patient 3 Normal Rangea Family 1, Patient 2 (II:3) Normal Rangea
Complex I 9 22 32–149 3 70–149
Complex II 164 120 53–160 139 80–110
Complex III n.t.b n.t.b n.t.b 3 31–170
Complex IV 21 13 53–283 2 50–138
Citrate synthasec 344 125 55–152 319 66–139
a The observed range was determined on at least nine muscle biopsies obtained from children lacking evidence of RC disease. Note that patient 2 was assayed
at a later time to the other patients.
b n.t. denotes not tested.
c Citrate synthase activity was expressed relative to protein.Cedars-Sinai Medical Center, Los Angeles). Once he was found to
have a primary RC disorder, he was subjected to trials of vitamins,
cofactors, and other pharmacological agents over a number of
years, including folic acid, coenzyme Q, vitamin C, vitamin E,
nicotinamide, riboﬂavin, carnitine, and creatine, none of which
were found to be of any obvious clinical beneﬁt or to have a
positive impact on blood lactate levels.
His younger sister (II:3; Figure 1) also developed a transfusion-
dependent sideroblastic anemia in infancy and went on to have
progressive muscle weakness, following a trajectory similar to
her brother’s. She also developed swallowing difﬁculties with
weakened pharyngeal peristalsis, ﬁrst apparent at the age of 15
years. Because of worsening dysphagia, she had a gastrostomy in-
serted for enteral nutrition. When last reviewed at 16 years of age,
her height was in the 6th percentile and weight was below the 3rd
percentile. She was pale with a hyperdynamic circulation. She had
no hepatosplenomegaly. Muscle tone was generally reduced, with
mild muscle weakness and normal deep tendon reﬂexes. Cogni-
tion was normal. She was unable to walk more than about 20 m
without having to stop to rest.
She too was found to have persistent lactic acidemia (2.5–
8.4 mmol/l). A muscle biopsy at 15 years of age showed reduced
complex I, III, and IV activities, with increased activities of
complex II and citrate synthase (Table 1).
The affected siblings have an older sister (II:1) and younger
identical twin brothers (II:4 and II:5), all of who are clinically well.
Family 2
The proband is the fourth child of ﬁrst-cousin parents of Lebanese
background and is not known to be related to family 1. She had
delayed motor milestones (unable to walk unaided until 3 years
of age) but was otherwise healthy until 7 years of age, when she
developed sideroblastic anemia, with a hemoglobin of 70 g/l
(normal range 115–140). She also had a raised blood lactate of
4.1 mmol/l, and her urine metabolic screen showed raised alanine
and lactate. Her parents refused to allow her to have blood
transfusions. They then embarked on an alternative-medicine
approach to her care, which included a raw protein powder
preparation, an algal-based preparation, mineral salts, lipoic
acid, B group vitamins, regular intramuscular pyridoxal-5-phos-
phate, and oral coenzyme Q10. When diligently taking these
preparations, the family believed that her hemoglobin could be
maintained between 80 and 110 g/l, and when not taking these
treatments her hemoglobin could drop to as low as 40 g/l and
was associated with severe lethargy and weakness. In recent years
she had also been involved in a regular ﬁtness program. She has54 The American Journal of Human Genetics 87, 52–59, July 9, 2010been able to participate in running events (walking only) of up
to 10 km.
When last reviewed at age 24 years, she had a mild skeletal
myopathy and mild peripheral muscle weakness, with normal
deep tendon reﬂexes. The rest of her general physical examination
was unremarkable.
A muscle biopsy when she was 8 years old showed lipid vacu-
oles. Speciﬁc stains for RC enzymes were not used. Muscle mito-
chondrial RC enzymology showed low activities of complex I
and IV (Table 1). Molecular testing for some of the common
mtDNA mutations (m.3243A>G, m.8344A>G, m.8993T>G, and
m.8993T>C) and for mtDNA deletions was normal.
She has two older brothers, an older sister, two younger sisters,
and a younger brother, all of whom are healthy and do not have
anemia or a myopathy. A maternal aunt is said to have had
transfusion-dependent sideroblastic anemia and a skeletal myop-
athy, but never had a muscle biopsy. She died at 26 years of age
after a lower-segment Caesarean section for her ﬁfth pregnancy
(the previous four having miscarried). The details of this are
unclear, but in the days before her death she developed a fever
and became comatose.
RC Enzyme Activities
Enzyme activities were determined as previously described.7
Genotyping and Linkage Analysis
Genome-wide SNP analysis was performed by the Australian
Genome Research Facility (Melbourne, Australia) with Affymetrix
250KNspI SNP chips. Data ﬁles for linkage analysis were generated
with LINKDATAGEN8 and were analyzed with MERLIN.9 Haplo-
types were generatedwith HaploPainter.10 A list of candidatemito-
chondrial genes was generated from MitoCarta.11 PCR-ampliﬁed
COX6C (MIM 124090), MRPL13 (MIM 610200), MRPS28 (MIM
611990), MRPS35 (MIM 611995), TIMM13 (MIM 607383), and
YARS2 cDNA or YARS2 gDNAwas sequenced by Macrogen (Korea).
Control genomic DNA was screened by a PCR-RFLP test utilizing
a MboII restriction site abolished by the c.156C>G mutation
(primers 50-AGTAGGTGGGTGTGGTGGG-30, 50-CAGCAGCGCA
AGTAGATGAC-30).
Immunoblotting
Skeletal muscle and ﬁbroblast samples were lysed as previously
described12 and resolved by 10% Bis-Tris precast gels (Invitrogen).
For immunoblot analysis, polyvinylidene ﬂuoride (PVDF)
membranes were probed with 1:200 anti-YARS2 (AP7838b, Ab-
gent), 1:500 anti-OXPHOS cocktail (consisting of ﬁve antibodies,
for detection of each of the ﬁve RC complexes; MitoSciences),
1:5000 anti-GAPDH (Millipore), or 1:1000 anti-mitoﬁlin (Mito-
Sciences) overnight at 4C and then with either 1:2500 ECL anti-
rabbit or anti-mouse IgG horseradish peroxidase (HRP; GE Health-
care) for 2hr at roomtemperature (RT).Membranesweredeveloped
with enhanced chemiluminescence (ECL) reagents and exposed to
HyperﬁlmECL. Filmswere scanned on aMicrotek ScanMaker 8700
and analyzed with ImageQuant software (GE Healthcare).
Immunoﬂuorescence
Muscle sections (0.8 mm) were ﬁxed and dehydrated.13 Muscle
sections were probed with 1:100 COI (complex IV subunit 1)
antibody (Invitrogen) O/N at 4C and then 1:250 anti-mouse
AlexaFluor555 (Invitrogen) and 1:1000 TOPRO-3 (Invitrogen) for
2 hr at RT. Images were taken on a Leica SP2 scanning laser
confocal microscope.
Mitochondrial Protein-Synthesis Assay
Assays were performed on myotubes and ﬁbroblasts as previously
described.14 Myotubes were generated by transdifferentiation of
ﬁbroblasts12 with an adenoviral MyoD vector. Fibroblasts were
transduced at 70%–80% conﬂuence with 500 transforming units
in the presence of 0.5 mg/ml Polybrene (Sigma). Mitochondrial
protein-synthesis assays were performed on myotubes after
6 days of differentiation.
Cloning and Aminoacylation Assay
Recombinant p.F52L YARS2 was generated for use in functional
assays. YARS2 was PCR ampliﬁed from patient DNA and cloned
into a TOPO TA vector (Invitrogen). A BamHI and BglII doubly
digested fragment containing the DNA mutation was then
subcloned into the wild-type YARS2 vector,15 from which the cor-
responding fragment had been removed. Recombinant wild-type
and p.F52L YARS2 were expressed and puriﬁed from E. coli
as previously described.15 Tyrosylation assays were performed
according to previously described methods.15 Apparent kinetic
parameters were determined from Lineweaver-Burk plots in the
presence of either wild-type or mutated (p.F52L) YARS2 (diluted
in 100 mM HEPES-NaOH [pH 7.4], 1 mM DTT, 5 mg/mL bovine
serum albumin, and 10% glycerol) and native E. coli tRNATyr
(Sigma) with concentrations ranging from 4 to 17 mM. Both
wild-type and mutant enzymes were used at concentrations of
23 and 35 nM, respectively. Experimental errors on kcat and Km
varied at most by 20%. Numerical values are averages of at least
two independent experiments.Results
We investigated the cause of MLASA in three patients from
two apparently unrelated consanguineous families. RC
enzyme analyses of muscle biopsies revealed functional
defects of complexes I, III, and IV enzyme activity relative
to citrate synthase activity in affected patients (Table 1;
note that complex III was not tested in all patients).
Enzyme activities were within normal limits in ﬁbroblasts
(data not shown).
Genome-wide SNP-based homozygosity analysis was
performed in the family with two affected childrenTh(Figure 1A) after PUS1mutation screening proved negative.
Regions of homozygosity common to the affected family
members were identiﬁed within ﬁve chromosomes:
2p25.1-p25.3 (10.6 cM), 8q12.1-q24.12 (16.4 cM),
12p12.1-q13.11 (13.2 cM), 18p11.31-q12.1 (32.4 cM),
and 19p13.3 (5.6 cM) (Table S1, Figure S1). The candidate
gene set was reﬁned by cross-referencing to genes that ex-
pressed a mitochondrially localized protein with the Mito-
Carta database,11 narrowing the list to 28 candidate genes
(Table S1). Six of these genes were sequenced, with no
mutations found in COX6C, MRPL13, MRPS28, MRPS35,
or TIMM13. YARS2, which encodes the human mitochon-
drial tyrosyl-tRNA synthetase, was among the ﬁrst genes
selected for sequencing, given the key role of aminoacyl-
tRNA synthetases (ARSs) in protein synthesis, and previous
reports of pathogenic mutations in the mt-ARS genes
DARS2 (MIM 610956) and RARS2 (MIM 611524) causing
neurological disease and lactic acidosis.16 A homozygous
c.156C>G (p.F52L) mutation was identiﬁed in YARS2 in
the affected children but not in the unaffected children,
whereas both parents were heterozygous (Figure 1B).
Phenylalanine 52 lies in the catalytic domain of YARS2
within the b1-strand and close to the ‘‘ins1’’ insertion
domain and is conserved in vascularized metazoans17
(Figure 1C). We subsequently identiﬁed the same homozy-
gous mutation in another MLASA patient (Table 1) from
a second consanguineous family. Both families were of
Lebanese origin, and haplotype mapping (data not shown)
suggests that they may carry a founder mutation that
arose on a relatively common haplotype deﬁned by three
SNPs that span the YARS2 gene. The haplotype consisting
of rs1183094, rs17541794, and rs11539444 has an inferred
haplotype frequency of 0.82 among the Lebanese popula-
tion based on haplotype frequency calculations using data
from 50 Lebanese control individuals with HAPLOVIEW.18
The YARS2 mutation was not found in 220 control chro-
mosomes, including 104 of Lebanese origin.
Because myopathy was a major symptom of the YARS2
mutation, we examined YARS2 expression in patient
muscle and its effect on RC complexes. Immunoblot anal-
ysis of skeletal muscle from patient II:3 revealed that
mutant YARS2 was expressed in patient muscle at slightly
reduced levels relative to three age- and sex-matched con-
trols (Figure 2A), with broadly normal levels of YARS2
observed in ﬁbroblast lines (Figure S2). Abnormal RC com-
plex I, III, and IV enzymatic function associated with the
YARS2 mutation (Table 1) was supported by immunoblot-
ting (Figure 2A) and immunolabeling (Figure 2B) of patient
skeletal muscle. Immunoblot analysis of subunits for RC
enzyme complexes, dependent upon RC complex forma-
tion for protein stability, revealed a severe reduction in
complex I (subunit NDUFB8), III (subunit core 2), and IV
(subunit 2) in patient muscle, relative to controls (Fig-
ure 2A). Immunolabeling of skeletal muscle cryosections
from patient II:3 also showed a marked reduction in levels
of complex IV (subunit 1) (Figure 2B). Levels of complex II
(subunit FeS) were elevated in patient muscle (Figure 2A),e American Journal of Human Genetics 87, 52–59, July 9, 2010 55
Figure 2. Effect of the YARS2 Mutation on Skeletal Muscle RC
Protein Expression
Immunoblot analysis of YARS2 and the RC complexes in (A)
patient II:3 muscle (P2) and three controls (C1, C2, C3). A 1 min
exposure of speciﬁc subunits of the ﬁve RC complexes (I–V)
detected by the anti-OXPHOS cocktail are shown on one blot.
An additional shorter exposure (5 s) of complex V subunit a is
shown for clarity. Note that these subunits are labile if the RC
complex is not fully assembled. GAPDH and mitoﬁlin were used
as loading controls; however, both were affected. Five micrograms
of total protein was loaded, and equivalent loadings were con-
ﬁrmed by Coomassie staining.
(B) Immunolabeling of patient II:3 and control muscle cryosec-
tions with CO1 (complex IV, subunit 1; red) and nuclear staining
with TOPRO-3 (blue). The scale bar represents 76 mm.in agreement with RC enzymology results showing in-
creased activity of complex II (Table 1). Complex II is the
only RC complex that does not contain mitochondrially
encoded subunits, suggesting that the dysfunction in
complexes I, III, and IV may be related to the requirement
for mitochondrially encoded subunits to form functional
complexes. Complex V, which was not assayed for
enzyme activity, was investigated by immunoblotting.
The nuclear-encoded subunit a of complex V was elevated56 The American Journal of Human Genetics 87, 52–59, July 9, 2010in patient muscle on immunoblotting (Figure 2A). Accu-
mulation of subcomplexes containing subunit a when
mitochondrial subunits are defective has been reported
previously.19 Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and mitoﬁlin were used as loading controls;
however, the levels of both also differed from controls.
Coomassie staining was used to conﬁrm equivalent load-
ings predicted by protein assay. Patient muscle showed
decreased levels of the glycolytic enzyme GAPDH and
increased levels of mitoﬁlin, an inner mitochondrial mem-
brane protein with critical functions in mitochondrial
fusion and ﬁssion (Figure 2A). These changes are presum-
ably secondary to the mitochondrial proliferation and
myopathic changes that have occurred in response to the
YARS2 mutation. Immunoblotting of patient ﬁbroblasts
showed only minor, if any, decrease in levels of RC
subunits relative to loading controls and no change in
GAPDH and mitoﬁlin levels (Figure S2).
Because YARS2 encodes mitochondrial tyrosyl-tRNA
synthetase, we hypothesized that the p.F52L mutation
may result in reduced mitochondrial protein synthesis.
There are 37 genes encoded by mtDNA: 24 are involved
in mt translation and 13 encode subunits of the RC.3
A mitochondrial protein-synthesis assay involving
[35S]-methionine pulse-chase labeling of patient myotubes
revealed decreased levels of mitochondrially encoded
protein subunits of RC complexes III (cytb), IV (CO1,
CO2/3), and V (ATP6) after [35S]-methionine pulse-chase
labeling of patient myotubes (Figure 3A). Reduced
steady-state levels of complex IV (CO1, CO2) subunits
and complex I (ND1) subunits were conﬁrmed by immu-
noblotting of mitochondrial extracts derived from patient
myotubes (Figure 3B). In contrast, steady-state levels of a
nuclear-encoded subunit of complex II (70 kDa) were
unaffected. These data suggest that the p.F52L YARS2
mutation leads to a deﬁciency in mitochondrial protein
synthesis and thus a reduction in RC complexes I, III, IV,
and V, which contain seven, one, three, and two mito-
chondrially encoded subunits, respectively.3 No signiﬁ-
cant defect in mitochondrial protein synthesis was
observed in ﬁbroblasts (Figure S3). Because immunoblot
analysis showed that mutant YARS2 levels were close to
normal in patient muscle, the apparent inability to supply
sufﬁcient mitochondrially encoded subunits of the RC
may be due to a functional defect in enzyme activity of
mutant YARS2.
Functional assays were performedwith puriﬁed recombi-
nant YARS2 to examine the consequence of the p.F52L
substitution upon YARS2 enzymatic activity. An aminoa-
cylation assay, measuring incorporation of [14C]-tyrosine
into E. coli native tRNATyr substrate, showed that p.F52L
YARS2 was catalytically active but with a ~2-fold reduced
rate as compared to the wild-type protein (kcat ¼ 55
versus 128 3 103 s1). The afﬁnity of p.F52L YARS2 for
tRNATyr was also reduced as indicated by an increased Km
(Km ¼ 3.9 versus 1.2 mM). Overall, there was a 9-fold loss
in catalytic efﬁciency (kcat / Km) in p.F52L YARS2.
Figure 3. The Mutation in YARS2 Results
in Reduced Mitochondrial Protein
Synthesis in Patient Myotubes
(A) SDS-PAGE phosphorimaging analysis
of [35S]-methionine-labeled mitochondrial
proteins from patient (P1 ¼ family 2, P2 ¼
II:3) and control (C1, C2) myotubes. Mito-
chondrially encoded subunits of complex I
(ND1, ND2, ND3), complex III (CYB),
complex IV (CO1, CO2, CO3; note that
CO2 and CO3 comigrate), and complex
V (ATP6, ATP8) are shown. An additional
band (*) seen in patient samples may
represent a degradation or incomplete
translation product.
(B) Immunoblot of selected mitochon-
drial- (complex I; ND1, complex IV; CO1,
CO2) and nuclear-encoded (complex II;
70 kDa) RC subunits in patient myotubes.Discussion
Here we report the identiﬁcation of a YARS2 mutation as
a cause of MLASA in three patients from two apparently
unrelated consanguineous families. Analysis of a control
cohort suggests that this may be a founder mutation in
the Lebanese population.Figure 4. Interaction Model of Human YARS2 with tRNA
The model shows the crystal structure of the enzyme17 (without
the S4-like C-terminal domain) on which one tRNATyr molecule
has been docked according to its location in the crystal structure
of a bacterial tryosyl-tRNA synthetase and tRNATyr complex.31
The two monomers are distinguished by dark- and light-green
color with the ﬁrst b strand encompassing residue 52 (p.F52L),
shown as the mutant L52, highlighted in purple. Note the prox-
imity of L52 with the accepting end of tRNA shown as orange.
ThThemutation results in reduced tRNATyr aminoacylation
efﬁciency. Analysis of the YARS2 crystal structure shows
that the p.F52L mutation lies near the catalytic center
where tRNA is tyrosylated17 and suggests an effect of F52
for recognizing and/or stabilizing the amino acid-accept-
ing helix of tRNATyr that is lost in the mutant (Figure 4).
The reduction in aminoacylation efﬁciency results in
defective mitochondrial protein synthesis. Reduced avail-
ability of mitochondrially encoded RC complex subunits
is probably rate limiting for RC complex assembly, under-
lying complex I, III, and IV RC dysfunction, each of which
contains mitochondrially encoded subunits. It appears
that ﬁbroblasts can maintain sufﬁcient levels of mito-
chondrially encoded RC components in the presence of
this mutation; however, RC deﬁciency is manifest in
muscle, possibly because of the higher requirements for
RC components in muscle.20–22
The YARS2 mutation gives rise to a unique phenotype
compared to other ARS mutations, despite their similar
roles in protein synthesis. However, the possibility that
mutations in other ARS genes could cause MLASA should
not be excluded in patients with unidentiﬁed mutations.
Mutations reported in both cytoplasmic and mitochon-
drial ARS genes have primarily affected the central nervous
system16 whereas the YARS2 mutation does not appear to
have any effects on brain structure or function. The reduc-
tion in oxidative phosphorylation capacity that results
from the RC deﬁcits would explain the myopathy, lactic
academia,23 and sideroblastic anemia.24 In addition,
YARS2 may have noncanonical functions, as is known for
many ARSs,16,25 which may be affected by this mutation
and thereby contribute to the unique phenotype compared
to those resulting from DARS2 and RARS2 mutations.
The YARS2 phenotype more closely resembles that
arising from PUS1 mutations because both are associated
with MLASA. Onset of symptoms was at an earlier age
(infancy–childhood) than generally reported for PUS1e American Journal of Human Genetics 87, 52–59, July 9, 2010 57
mutation-positive patients (childhood–adolescence).5,26As
for PUS1 mutations,5 variability in severity of the
phenotype was observed for the YARS2 mutation. The
reduced severity of the disease inone family raises thepossi-
bility that an unknown modiﬁer allows compensation for
the decreased enzyme activity in vivo, or that perhaps
a chaperonemoleculewith a stabilizing effectmaybe found
among the alternative treatments of the less severely
affected patient. It is also possible that the more severely
affected family carries an additional mutation in another
gene involved in mitochondrial RC homeostasis.
The pathogenesis of YARS2 and PUS1 mutations may be
similar. PUS1 mutations result in loss of pseudouridine in
some tRNAs, which may affect protein synthesis.6 The
second anticodon position of tRNATyr is invariably uridine
and is pseudouridylated in cytosolic human tRNATyr
(ref. 27) and possibly in mitochondrial species. In patients
with pathogenic PUS1 mutations, there is greatly reduced
pseudouridylation6 that could occur at positions such as
U35, where pseudouridylation has been shown to partici-
pate in tyrosine identity.28,29 This could imply a decreased
tyrosylation capacity of hypomodiﬁed tRNATyr and there-
fore suggests that the marked clinical similarity between
patients with PUS1 and YARS2 mutations is through a
common mechanism triggered by altered tRNATyr
charging. However, it has also been proposed that the clin-
ical features associated with PUS1mutations may be due to
effects on non-tRNA molecules.30
In conclusion, the p.F52L YARS2 mutation results in
reduced mitochondrial tRNATyr aminoacylation activity
leading to a reduction in mitochondrial protein synthesis
and is another cause ofMLASA. It remains to be established
whether mutations in YARS2will be frequently observed in
other cases of MLASA and other clinical phenotypes where
sideroblastic anemia is a predominant feature.Supplemental Data
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